1. Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories

2. Confidential Page 2 West Nile Virus Update Abbott’s commitment to WNV Abbott’s commitment to WNV will continue as needed to aid in understanding evolution of markers associated with infection Abbott’s Research WNV IgM assay : Abbott’s Research WNV IgM assay : Cutoff set based on human population studies, experimental infection studies in primates Repeatably reactive specimens were characterized with other serologic assays to confirm reactivity Supplemental tests from various sources have been utilized to aid in setting cutoff for Abbott’s test

3. Abbott Laboratories Confidential Page 3 West Nile Virus Update Recent observations indicate: Recent observations indicate: Considerable overlap of WNV RNA detection and IgM detection in the early stage of infection Low level viremics may be negative by minipool NAT and reactive by WNV IgM Infectivity studies may be required to determine transmissibility of low level viremic specimens More sensitive IgM assays have greater overlap with WNV RNA detection than less sensitive assays As WNV IgM tests become more sensitive, there are fewer options for confirmatory tests with appropriate sensitivity

4. Abbott Laboratories Confidential Page 4 West Nile Virus Specificity issues with WNV IgM assays for WNV Specificity issues with WNV IgM assays for WNV:. Cross reactivity 1. Cross reactivity A repeatably reactive test result may be induced by flaviviruses other than WNV due to relatively high degree of amino acid homology between proteins of WNV and other flaviviruses 2. Confirmatory testing Low level reactives may be difficult to confirm Follow-up samples may be required

5. Abbott Laboratories Confidential Page 5 RegionDengue*YFVTBEVMVJEVSLE Core41.427.1~21.965.961.860.3 PreM/M37.638.630.277.274.265.9 ENV50.145.244.179.378.873.3 NS152.343.443.176.177.865.2 NS2A28.527.921.364.865.649.8 NS2B33.128.525.274.067.952.7 NS363.652.146.780.581.772.9 NS4A40.435.634.277.277.863.1 NS4B40.732.027.164.665.556.9 NS566.560.960.182.681.275.3b * Average of Dengue type 1 through 4: analyses performed at Abbott Laboratories Amino Acid Sequence Homology Comparison of percent identity of West Nile Virus vs. Dengue, Yellow Fever, Japanese Encephalitis and St. Louis Encephalitis Viruses

6. Abbott Laboratories Confidential Page 6 SerumSLEJEWNDEN2YFPOW 14.967.7516.742.451.821.56 24.813.7716.684.132.141.75 35.459.6716.084.091.611.44 44.7610.0717.193.321.621.3 Positive Control 6.58.26.347.453.964.5 ELISA Cross-reactivities of WNV IgM Test (S/N values as reported by CDC) * 1:400 screening dilution of WNV patient serum

7. Abbott Laboratories Confidential Page 7 Anti-IgM Coated Solid Phase Serum Added Diluent Antigen Added Diluent Red Conjugate Added Diluent Blue Two-Step IgM Capture EIA Timing: 1 hr/37 o C/Static 2 hr/37 o C/Static

8. Abbott Laboratories Confidential Page 8 West Nile Virus Studies Volunteer blood donors from 2002 Volunteer blood donors from 2002 Based on previous population studies the cut-off was provisionally set at S/N = 5.0 Experimentally infected rhesus monkeys* Experimentally infected rhesus monkeys* Daily bleeds for 2 wks Natural history of WNV *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

9. Abbott Laboratories Confidential Page 9 Serologic Profile of WNV Infection in Experimentally Infected Monkeys + -------- ++++ - + + ----------- +++ -- + - + + Nested RT-PCR Virus Isolation *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

10. Abbott Laboratories Confidential Page 10 Day #Virus (log)RT-PCTIgM (S/N)IgG S/NHI (titer)CF (titer)PRNT (titer) 0-- 1.0 --- 1-+ --- 22.0+ 1.01.1--- 31.0+ 1.1--- 41.7+ 1.01.2--- 51.7+ 1.01.1--- 6-+ 1.31.0--- 7-+ 1.61.0--- 8-- 2.11.0--- 9-+ 3.31.0--- 10-+/- 8.31.1--1:10 11-- 18.31.11:20- 12-- 45.21.31:160-1:20 13-->65.61.51:640-1:40 14-->65.62.01:640161:20 21-->65.67.1ND 1:80 28-->65.68.21:128064ND 45 63 ---- ---- 38.7 21.6 9.0 15.9 1:640 1:1280 64 ND 1:512 Serologic Profile of Experimentally Infected Macaque #810 *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

11. Abbott Laboratories Confidential Page 11 Serologic Profile of WNV Infection in Experimentally Infected Monkeys Nested RT-PCR Virus Isolation + -------- +++ - + ----------- - --- - - + - - - - *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

12. Abbott Laboratories Confidential Page 12 Day #VirusRT-PCTIgM (S/N)IgG S/NHICFPRNT 0-- 1.0 --- 1-+ 0.80.9--- 21.7+ 1.11.0--- 3-+ 0.81.0--- 4-+ --- 5-- 0.9 --- 6-+ 1.11.0--- 7-- 1.41.0--- 8-- 1.50.9--- 9-- 2.31.1--- 10-- 3.31.3--- 11-- 4.41.4--- 12-- 8.41.61:20 8- 13--15.22.21:40321:10 14--27.62.61:80321:20 21--27.99.61:320641:80 28--9.39.21:16064ND 45 63 ---- ---- 2.3 7.7 7.0 1:160 16 8 ND 1:1280 Serologic Profile of Experimentally Infected Macaque #J840 *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

13. Abbott Laboratories Confidential Page 13 Day #Virus log PFU’s (pos/total) RT-PCR (pos/total) IgM (S/N)IgG S/NHI (titer)CF (titer)PRNT (titer) 0--1.0 --- 1-5/5 +0.91.0--- 21.7 (5/5+)5/5 +1.11.0--- 32.0 (3/5+)5/5 +1.0 --- 41.0 (2/5+)5/5 +1.11.0--- 51.7 (2/5+)3/5+1.11.0--- 6-3/5 +1.31.0--- 7-1/5+1.51.0--- 8-0/5 +2.10.9--- 9-1/5 +3.31.0--- 10-1/5 +-11.91.01:20-1:10 11--18.31.11:40-1:20 12--30.91.31:8081:20 13--40.21.51:160161:40 14--50.82.11:320161:40 21--46.17.11:320321:80 28--27.08.21:16064ND 45--11.69.01:160161:640 63--3.47.01:160161:640 Summary of Serologic Profiles of Experimentally Infected Macaques Median Values *In collaboration with Dr. Tesh and associates at UTMB Galveston, TX and Dr. Marion Ratterree and associates at the Tulane National Primate Research Center, Covington, LA

14. Abbott Laboratories Confidential Page 14 Experimentally Infected Macaques A total of 38 of the 41 IgM reactive specimens (S/N>5.0) were confirmed by one or more supplemental assay A total of 38 of the 41 IgM reactive specimens (S/N>5.0) were confirmed by one or more supplemental assay 2 of 5 of the first bleed dates were confirmed by one or more supplemental assays A provisional cutoff was set an S/N greater than 5.0 and utilized for human studies A provisional cutoff was set an S/N greater than 5.0 and utilized for human studies

15. Abbott Laboratories Confidential Page 15 IgM Detection in a Selected Population* Volunteer blood donations from 2002, from centers considered at “high risk” for WNV Infection – Dr. L Tobler Blood Centers of the Pacific; Dr. Michael Busch, America’s Blood Centers

16. Abbott Laboratories Confidential Page 16 NumberIgM (S/N) retest IgM 2 (S/N) PRNT Titer WNV IgG retest Supplemental Testing 1>155.5>111.148.864014.520.1Pos 2142.4>111.145.0128085.299.8Pos 3127.3>111.147.13208.78.4Pos 4110.7109.224.732024.638.9Pos 5103.9108.832.416029.120.1Pos 691.195.926.416063.857.8Pos 759.978.320.464081.445.6Pos 831.632.118.4Neg0.8NDNeg* 910.19.64.4Neg1.3NDNeg* 107.98.75.1Neg1.1NDNeg* 117.85.04.4Neg0.5NDNeg* 127.712.45.8Neg.0.5NDNeg* 135.510.44.4Neg0.6NDNeg* Serologic Profile of Repeatably Reactive Human Specimens Additional supplemental testing is being performed Volunteer blood donations from 2002, from centers considered at “high risk” for WNV Infection – Dr. L Tobler Blood Centers of the Pacific; Dr. Michael Busch, America’s Blood Centers

17. Abbott Laboratories Confidential Page 17 SUMMARY Assay Format Finalized EIA on polystyrene beads Capture IgM completed in 3.5 hours at 37° C Preliminary evaluation of IgM testing indicates: In experimentally infected primates, IgM was detected by day 10 post infection The provisional cutoff set at S/N 5.0 appears to provide adequate specificity Specificity improvements may be made in the future if needed Research studies will continue utilizing current provisional cutoff, while evaluating supplemental testing (confirmatory) algorithms